Member Info for cindercone

Why would anyone want a takeover anyway? If what Avacta has is as good as we're all dreaming of, the thought of letting this go for a fiver is a joke. License, keep collecting pipeline data until the SP is £15 and maybe we can think about it.

The trial began in August 2021 in ONE patient. That's 3.3 years not five and one patient is statistically meaningless. We're looking at 1H 2026 at the earliest so nobody should be discussing a takeover before then.

"If Standard Dox doesn't have 'delayed Cardiotoxicity' why would AVA6000 administered Dox?"

But standard dox DOES cause delayed cardiac toxicity, and even if AVA6000 releases dox mainly in tumours some systemic exposure still occurs.

IMO, more patients required, longer follow-up required - and that's the data we need to see.

So much garbage spoken here by the usual clueless idiots that pump today and dump tomorrow pretending they're experts. As much as I'm excited by the potential here, simple fact is Avacta is nowhere near a takeover. Much more compelling data is required that there is no evidence that strong/repeat dosing will not cause delayed heart damage/cardiomyopathy months or years after treatment. License deal, quite possible - maybe even probable. Takeover - not a chance at this stage imo.

It's a complete waste of time giving any significance to the share trades published on this website.

SP almost at an all-time low 😣

However, a lot of attention being paid here to Trust Pilot ratings, but all three Huddled Group stores are at the top end or above the weighted Trust Pilot average of 3.5 - 4.2. Discount Dragon is especially impressive considering it has 22,000 reviews, which is well above average for statistical reliability.

These ratings have the potential to improve further as THG becomes fully functional, but Huddled Group demonstrates excellent service levels for an online retailer with such logistical challenges. Then there's Mike Ashley whose Sport Direct empire is essentially based on the same "buy low, sell fast" principle - it doesn't make much vision to see the potential at these prices.

That Aldebaran post has to be the dumbest I've ever read on here... and that's saying something with the likes of Wynbore, Touk and Thorgonson boring everyone with their daily gash.

Basically, the stupid mugs are having their shares stolen off them on the cheap.

@russell1

Quite possibly, but why do any hasty deals when further data reveals disease reversal?

IMO, the only thing missing here is substantive patient outcome data. Early-stage data has demonstrated compelling tumor-targeted activation and safety profiles but the missing piece remains statistically significant, peer-reviewed outcomes showing durable tumor regression or survival benefit, which might simply require more patience (there are ethical and regulatory around clinical trial data disclosure) or a broader patient cohort.

In yesterday's call it was indicated that some patients experienced a reversal of disease progression, but this is anecdotal rather than based on fully verifiable datasets. Hopefully, this is just a matter of time, because I wouldn't want to be out if and when that data drops because you're potentially looking at a several hundred per cent increase in one session.

I'm just surprised at how short people's memories are - was only last week MKA TSX rose 230% in a day. Question is, why? Pump and dumps don't typically create that much movement, I think it's more likely insider trading US side. Someone knows something that will be revealed soon enough. Anyone stupid enough to sell before the dust has even settled needs their head examined - but that's day traders for you.

When the idiots sell, buy more.

You can't get it work either, which is why you're here all day whoring your opinions in a lame attempt to influence others.

There are good raises and bad raises - this is a good raise.

Has someone seen some data?

@opti_mystic

I'm also confident the board will deliver - why else would Heights postpone bond repayments? Unless something has leaked, you'd have to be f*cking bonkers to sell now rather than wait to see how this pans out. Positive data + a funding deal that wipes out debt could take this from 0.67p to practically anything. Therapeutic Hemogenyx Pharmaceuticals hit £15 simply based on excellent data and no pressing requirement for funding.

I don't think that type of a raise will go down well at all. You can't be telling shareholders that the technology is groundbreaking, you're talking to loads of private investors and have a high degree of confidence in a partnership only to go back the markets and get the begging bowl out. That would stink, especially as it would presumably be accompanied by lackluster data.

Next few weeks are pivotal IMO. AVACTA will either fly into the pounds or be back to 30p in short order.

I also bought silver on Clive Thompson's recommendation. Up 45% so far - seems like I picked the right stock!

aldebaran's harsh response is doing him a favour. anyone who thinks it's a good idea to base their investment decisions on what someone predicts an sp will be in 6 months clearly knows nothing about what they're invested in or investment in general. telling him that rather than bull****ting will allow him to make better decisions in the future, assuming he's mentally equipped.

Great presentation, even AI Brian sounded bullish for a couple of seconds - although not entirely convinced his emotional investment quite matches CC's.